FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1086-1087 October 9, 1997 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Jacobson, J. M. PubMed Citation

To the Editor: Jacobson et al. (May 22 issue)¹ report encouraging results in their placebo-controlled trial of thalidomide for aphthous ulceration in patients with human immunodeficiency virus (HIV) infection. However, potential enthusiasm must be muted because of the preliminary nature of the findings and the unanticipated safety issues raised by the results. The data are based on an interim analysis of only 57 patients. Even in this small sample, major adverse events were seen during the four-week treatment phase, including grade 4 neutropenia in two thalidomide recipients. Approximately half the study participants either discontinued the study medication or had a . . . [Full Text of this Article]

References

Related Letters:

Professionalism
Needham C. W., Granat P.
Extract | Full Text  
N Engl J Med 1998; 338:66, Jan 1, 1998. Correspondence

This article has been cited by other articles:

• Dios, P. D., Sopena, B., Cameselle, J., Butron, M., Crespo, M., Ocampo, A. (2000). Thalidomide for the Treatment of Acquired Immunodeficiency Syndrome-Associated Refractory Oral Ulcers. Arch Otolaryngol Head Neck Surg 126: 89-92 [Abstract] [Full Text]  
• Fye, W. B. (1998). Managed Care and Patients With Cardiovascular Disease. Circulation 97: 1895-1896 [Full Text]  
• Needham, C. W., Granat, P. (1998). Professionalism. NEJM 338: 66-66 [Full Text]